Serotonin receptor ligands and the treatment of obesity

Current Opinion in Investigational Drugs

Volumn 5, Issue 4, 2004, Pages 377-388

  Vickers, Steven P ^a   Dourish, Colin T ^b  

^a RenaSci Ltd   (United Kingdom)

^b Vernalis PLC   (United Kingdom)

Author keywords

Appetite; Eating; Obesity; Receptors; Satiety; Serotonin

Indexed keywords

LIGAND; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT;

ANIMAL; CHEMISTRY; CLASSIFICATION; HUMAN; METABOLISM; OBESITY; REVIEW;

ANIMALS; HUMANS; LIGANDS; OBESITY; RECEPTORS, SEROTONIN; SEROTONIN AGENTS;

EID: 3042571673     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. National Audit Office, UK. Controller and Auditor General: Tackling Obesity in England. The Stationary Office, London, UK (2001) February 8: Report No HC220 Session 2000-1.
2. Bonow RO, Eckel RH: Diet, obesity and cardiovascular risk. N Engl J Med (2003) 348(21):2057-2058.
3. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB: Years of life lost due to obesity. J Am Med Assoc (2003) 289(2):187-193.
4. Wolf AM, Colditz GA: Current estimates of the economic costs of obesity in the United States. Obes Res (1998) 6(2):97-106.
5. Blundell JE: Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obes (1977) 1(1):15-42.
6. Dourish CT: 5-HT receptor subtypes and feeding behaviour. In: 5-Hydroxytryptamine-CNS Receptors and Brain Function. Bradley PB, Handley SL, Cooper SJ, Key BJ, Barnes NM (Eds), Pergamon Press, Oxford, UK (1992) 85:179-202.
7. Garattini S, Mennini T, Bendotti C, Invernizzi R, Samanin R: Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system. Appetite (1986) 7(Suppl):15-38.
8. Gundlah C, Martin KF, Heal DJ, Auerbach SB: In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor. J Pharmacol Ther (1997) 283(2):581-591.
9. Rowland NE, Carlton J: Neurobiology of an anorectic drug: Fenfluramine. Prog Neurobiol (1986) 27(1):13-62.
10. Guy-Grand B: Clinical studies with D-fenfluramine. Am J Clin Nutr (1992) 55(1 Suppl):173S-176S.
11. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med (1997) 337(9):581-588.
12. Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR: A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol (1998) 125(2):301-308.
13. Hoyer D, Hannon JP, Martin GR: Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav (2002) 71(4):533-554.
14. Dourish CT: Multiple serotonin receptors: Opportunities for new treatments for obesity? Obes Res (1995) 3(Suppl 4):449S-462S.
15. 1A receptor antagonist. Behav Brain Res (1996) 73(1-2):337-353.
16. Dourish CT, Hutson PH, Curzon G: Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat. Psychopharmacology (1985) 86(1-2):197-204.
17. Dourish CT, Hutson PH, Curzon G: Characteristics of feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Brain Res Bull (1985) 15(4):377-384.
18. 1A receptors. Physiol Behav (2001) 73(1-2):223-227.
19. 1A receptors in the control of food intake in obese Zucker rats of different ages. Pharmacol Biochem Behav (2002) 72(1-2):403-409.
20. Hutson PH, Dourish CT, Curzon G: Neurochemical and behavioural evidence for mediation of the hyperphagic action of 8-OH-DPAT by 5-HT cell body autoreceptors. Eur J Pharmacol (1988) 129(3):347-352.
21. 1A presynaptic, but not postsynaptic receptor-mediated responses: Relationship to antidepressant-like action. Eur J Pharmacol (1987) 138(1):53-60.
22. Fletcher PJ: Dopamine receptor blockade in nucleus accumbens or caudate nucleus differentially affects feeding induced by 8-OH-DPAT injected into dorsal or median raphe. Brain Res (1991) 552(2):181-189.
23. Fletcher PJ, Davies M: Dorsal raphe microinjection of 5-HT and indirect 5-HT agonists induces feeding in rats. Eur J Pharmacol (1990) 184(2-3):265-271.
24. Fletcher PJ, Davies M: The involvement of 5-hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone. Br J Pharmacol (1990) 99(3):519-525.
25. Fletcher PJ: Opiate antagonists inhibit feeding induced by 8-OHDPAT: Possible mediation in the nucleus accumbens. Brain Res (1991) 560(1-2):260-267.
26. Fletcher PJ, Ming ZH, Higgins GA: Conditioned place preference induced by microinjection of 8-OH-DPAT into the dorsal or median raphe nucleus. Psychopharmacology (1993) 113(1):31-36.
27. 1A agonists and dopamine: The effects of 8-OH-DPAT and buspirone on brainstimulation reward. J Neural Trans (1991) 83(1-2):139-148.
28. Ho MY, Body S, Kheramin S, Bradshaw CM, Szabadi E: Effects of 8-OH-DPAT and WAY-100635 on performance on a time-constrained progressive-ratio schedule. Psychopharmacology (2003) 167(2):137-144.
29. Montgomery AMJ, Grottick AJ: Neurotransmitter system interactions revealed by drug-induced changes in motivated behavior. Pharmacol Biochem Behav (1999) 62(4):643-657.
30. 1A receptor antagonist, on feeding and 8-OH-DPAT-induced feeding in the rat. Br J Pharmacol (1994) 112:298P.
31. 1A receptor subtype. Psychopharmacology (1996) 125(2):168-175.
32. 1A receptor antagonists. Eur J Pharmacol (1998) 357(2-3):179-184.
33. 2C receptors. Neuropharmacology (2001) 41(2):200-209.
34. 1B agonists induce anorexia at a postsynaptic site. Eur J Pharmacol (1987) 141(3):429-435.
35. 1B receptor agonist CP-94253 reduces food intake and preserves the behavioural satiety sequence. Physiol Behav (1996) 60(3):933-939.
36. 1B) agonist that promotes satiety. Psychopharmacology (1997) 131(3):264-270.
37. Antin J, Gibbs J, Holt J, Young RC, Smith GP: Cholecystokinin elicits the complete behavioural sequence of satiety in rats. J Comp Physiol Psychol (1975) 89(7):784-790.
38. 2 receptor agonists using the post-prandial satiety sequence in rats. Psychopharmacology (1994) 113(3-4):369-377.
39. 1B agonist CP-94,253. Psychopharmacology (2002) 164(1):49-60.
40. 1B receptor ligands on appetite control in the rat. Br J Pharmacol (1998) 123:238P.
41. 1B receptor knockout mice have higher body weights than wildtypes. Physiol Behav (2001) 74(4-5):507-516.
42. Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F, Hen R: Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J Neurosci (1998) 18(14):5537-5544.
43. 2c receptor function. Eur J Neurosci (2003) 17(1):185-190.
44. 2C receptor mutant mice. Psychopharmacology (1999) 143(3):309-314.
45. 2C receptor agonist, and D-fenfluramine on feeding patterns in the rat. Psychopharmacology (2000) 152(3):256-267.
46. Boeles S, Williams C, Campling GM, Goodall EM, Cowen PJ: Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology (1997) 129(2):179-182.
47. Simansky KJ, Vaidya AH: Behavioral mechanisms for the anorectic action of the serotonin (5-HT) uptake inhibitor sertraline in rats: Comparison with directly acting 5-HT agonists. Brain Res Bull (1990) 25(6):953-960.
48. Lawton CL, Blundell JE: 5-HT and carbohydrate suppression: Effects of 5-HT antagonists on the action of D-fenfluramine and DOI. Pharmacol Biochem Behav(1993) 46(2):349-360.
49. 2A receptors in atypical antipsychotic drug actions. The Neuroscientist (1999) 5(4):254-262.
50. 1 receptors. Psychopharmacology (1989) 97(2):213-218.
51. 2A knockout mice. Am J Physiol Gastrointest Liver Physiol (2002) 282(5):G877-G893.
52. 2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology (1997) 36(2):233-239.
53. Nebigil CG, Choi DS, Dierich A, Hickel P, Le Meur M, Messaddeq N, Launay JM, Maroteaux L: Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA (2000) 97(17):9508-9513.
54. 1B receptors. Psychopharmacology (1988) 96(1):93-100.
55. Vickers SP, Benwell KR, Porter RH, Bickerdike MJ, Kennett GA, Dourish CT: Comparative effects of continuous infusion of mCPP, Ro 60-0175 and D-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br J Pharmacol (2000) 130(6):1305-1314.
56. 2C receptor modulation and the treatment of obesity. Diabetes Obesity Metab (1999) 1(4):207-214.
57. 2C receptor agonists as potential drugs for the treatment of obesity. Curr Top Med Chem (2003) 3(8):885-897.
58. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP: Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol (1998) 54(1):94-104.
59. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB: Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature (1997) 387(6630):303-308.
60. 2C receptor isoforms. Eur J Pharmacol (2001) 419(2-3):107-112.
61. 1C receptors mediate 1-3(chlorophenyl)piperazine-induced hypophagia. Br J Pharmacol (1991) 103(4):2016-2020.
62. 2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology (2003) 167(3):274-280.
63. 1C receptors. Br J Pharmacol (1988) 94(1):137-147.
64. 2C receptor levels in the rat. Br J Pharmacol (1998) 123(8):1707-1715.
65. Clifton PG, Barnfield AM, Curzon G: Effects of food-deprivation and mCPP treatment on the microstructure of ingestive behaviour of male and female rats. J Psychopharmacol (1993) 7:257- 264.
66. Hewitt KN, Lee MD, Dourish CT, Clifton PG: Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav (2002) 71(4):691-700.
67. 1C receptors and their therapeutic relevance. Curr Opin Invest Drugs (1993) 2(4):317-362.
68. 2C receptors in CHOK1 cells. Br J Pharmacol (1999) 128(1):13-20.
69. 2C receptor agonists. Pharmacol Biochem Behav (2001) 69(3-4):643-652.
70. 2C receptor antagonist. Neuropharmacology (1997) 36(4-5):609-620.
71. 2C receptor as potential antidepressants and anxiolytics. In: Trends in Drug Research. van der Groot J (Ed), Elsevier, Amsterdam, the Netherlands (1998):49-61.
72. 2C receptor agonists: Pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther (1998) 286(2):913-924.
73. 2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat. Prog Neuropsychopharmacol Biol Psychiatry (2002) 26(3):441-449.
74. Fletcher PJ: Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, metergoline and ritanserin. Psychopharmacology (1988) 96(2):237-242.
75. 1 receptors elicits feeding in satiated rats. Psychopharmacology (1989) 97(1):54-58.
76. 2C receptor antagonist. Neuropharmacology (1997) 36(4-5):621-629.
77. 2C serotonin receptors. Nature (1995) 374(6522):542-546.
78. 2C receptor gene. Nat Med (1998) 4(10):1152-1156.
79. 2C receptors in mediating fenfluramine-induced anorexia in rats. Br J Pharmacol (1995) 114:373P.
80. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, Lee CE et al: Activation of central melanocortin pathways by fenfluramine. Science (2002) 297(5581):609-611.
81. Heisler LK, Cowley MA, Kishi T, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Zigman JM, Cone RD et al: Central serotonin and melanocortin pathways regulating energy homeostasis. Ann NY Acad Sci (2003) 994:169-174.
82. Walsh AE, Smith KA, Oldman AD, Williams C, Goodall EM, Cowen PJ: m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (1994) 116(1):120-122.
83. 2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology (1997) 133(3):309-312.
84. Goodall EM, Cowen PJ, Franklin M, Silverstone T: Ritanserin attenuates anorectic, endocrine and thermic responses to D-fenfluramine in human volunteers. Psychopharmacology (1993) 112(4):461-466.
85. 2C receptor agonist, reduces feeding in rodents and produces weight loss in humans. Soc Neurosci Abstr (2001) 27(2):309.2.
86. Gallant DM, Bishop MP, Bishop G, O'Meallie L: U-22,934A: A controlled evaluation in chronic schizophrenic patients. Curr Ther Res (1967) 9(11):579-581.
87. 2B receptor agonist. 5th IUPHAR Satellite Meeting on Serotonin, Acapulco, Mexico (2002):P38.
88. 2C receptor agonist, VER-3323, on food intake. 5th IUPHAR Satellite Meeting on Serotonin, Acapulco, Mexico (2002):P13.
89. 2C receptor agonists. Bioorg Med Chem Lett (2004): in press.
90. 3 receptor antagonists in rats. Psychopharmacology (1995) 121(4):488-493.
91. 3 receptor antagonist, reduces palatable food consumption in the nondeprived rat. Neuropharmacology (1994) 33(6):805-811.
92. Talley NJ: Serotoninergic neuroenteric modulators. Lancet (2001) 358(9298):2061-2068.
93. Johnson BA, Oldman D, Goodall EM, Chen YR, Cowen PJ: Effects of GR 68755 on D-amphetamine-induced changes in mood, cognitive performance, appetite, food preference, and caloric and macronutrient intake in humans. Behav Pharmacol (1996) 7(3):216-227.
94. 6 receptor ligands and their biological functions. Curr Top Med Chem (2002) 2(6):643-654.
95. 6 receptors. Br J Pharmacol (1998) 124(3):556-562.
96. 6 antagonist, Ro 04-6790 on food consumption in rats trained to a fixed feeding regime. Br J Pharmacol (1999) 126:66P.
97. 6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology (2001) 41(2):210-219.
98. 6 receptor antagonism, a novel mechanism for the management of obesity. SMi Conf Obesity and Related Disorders, London, UK (2003).
99. 4 receptor mediated stimulation of gastric emptying in rats. Naunyn Schmeidebergs Arch Pharmacol (1995) 351(6):589-595.
100. 7 receptor antagonist, modulates REM sleep in rats. Br J Pharmacol (2003) 139(4):705-714.
101. 7 receptor knockout mice. Proc Natl Acad Sci USA (2003) 100(3):1375-1380.
102. Clemett DA, Cockett MI, Marsden CA, Fone KC: Antisense oligonucleotide-induced reduction in 5-hydroxytryptamine 7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. J Neurochem (1998) 71(3):1271-1279.
103. 2C ligands for the treatment of obesity and eating disorders. WO-03057674 (2003).
104. BIOVITRUM (Nilsson B, Tejbrant J, Pelcman B, Ringberg E, Thor M, Nilsson J, Jonsson M): Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotoninrelated diseases. US-06465467 (2002).
105. BRISTOL-MYERS SQUIBB (Robichaud AJ, Fevig JM, Mitchell IS, Lee T, Chen W, Cacciola J): Substituted pyridoindoles as serotonin agonists and antagonists. WO-02059129 (2002).
106. 2C receptor agonists. WO00109126 (2001).
107. PFIZER PRODUCTS INC (Chian PYC, Novomisle WA, Welch WM): Piperazine derivative 5-HT receptor ligands. WO-03000663 (2003).
108. 2C-related diseases. WO-00076984 (2000).
109. 2 receptors. WO2003064423 (2003).
110. 2C receptor agonists for treating CNS disorders. WO-00242304 (2002).
111. 2C agonists for treating sexual dysfunction. WO-02074746 (2002).
112. 6 receptor knockout mouse. US-06060642 (2000).
113. 6 modulators for the treatment of obesity, type II diabetes and CNS disorders. WO-02092585 (2002).
114. 6 antagonist useful for the treatment of obesity. WO-02008178 (2002).